Navigation Links
Heart smart: new drug improves blood flow

A new drug has been shown to improve blood flow in diseased arteries, reducing the risk of high blood pressure and heart attacks, a Monash University study published today reveals.

The finding is a significant development for the Monash team that, in conjunction with Bayer Health Care, hopes to use the drug as part of a revolution in the management of heart disease.

Dr. Harald Schmidt, Director of the Centre for Vascular Health and his colleagues at Monash University, Dr. Peter Schmidt and Barbara Kemp-Harper, say the next step will be to translate the research so it benefits patients. Clinical trials of the drug have already started for the treatment of acute heart failure.

Dr. Schmidt's team and colleagues in Germany and the US have previously shown that oxidative stress - the appearance of free radicals in the walls of arteries - is a key mechanism underlying cardiovascular disease.

"Free radicals contribute to the formation of arterial blockages. What's more, as the number of free radicals increases, they also interfere with the ability of the cells lining arteries to control the contraction and dilation of the arteries," Dr. Schmidt says. "The arteries stiffen and get blocked."

When a blockage occurs, the cells lining the arteries produce nitric oxide to signal to the arterial muscles that they need to dilate the artery and allow more blood through. But free radicals destroy a key enzyme that allows the arterial cells to respond in this way, so the signal doesn't get through.

However, the new drug ?developed by Bayer HealthCare ?reactivates the damaged enzyme.

"Our results show that the drug directly binds to and repairs the damaged enzyme. And as the number of free radicals increases, the drug starts working harder," says Dr. Schmidt.

The results have been published in the Journal of Clinical Investigation and the September issue of Nature Reviews/Drug Discovery.

Dr. Schmidt, toget her with clinical and basic science colleagues, is creating a new research centre at Monash with the aim of challenging orthodox thinking on heart disease and stroke.

"Vascular diseases are the number one cause of death worldwide. Yet we don't know enough about the causes to reliably identify and treat cases, let alone prevent these diseases," he says. "In up to 95 per cent of cases, the root causes of vascular diseases are still unknown. So clinicians have to rely on 'lifestyle' indicators and 'risk factors' such as high blood pressure and high cholesterol.

"However, not all people with high blood pressure or high cholesterol experience heart attack or stroke At the same time, many people without any apparent risk factors have unexpected heart attacks and strokes. We need a revolution in vascular diagnosis, treatment and prevention. This discovery is an important step along the way."
'"/>

Source:Research Australia


Related biology news :

1. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
2. Implanted Devices Detect High-Risk Heart Failure Patients
3. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
4. Special Imaging Study Shows Failing Hearts Are Energy Starved
5. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
6. Heart repair gets new muscle
7. Male Combat Veterans Rank High In Heart Disease Risk
8. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
9. Researchers Find Drug May Give Some Cardiac Protection 24 Hours After Heart Attack
10. Heart-healthy compound in chocolate identified
11. Heart has enough oxygen to survive hypothermia, CPR crucial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:1/4/2017)... 2017  CES 2017 – Valencell , the ... announced the launch of two new versions of ... biometric sensor modules that incorporate the best of ... expertise. The two new designs include Benchmark BE2.0, ... and Benchmark BW2.0, a 2-LED version of its ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... ... the CHI SCOPE Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). ... to examine vital clinical research issues such as trial performance metrics, patient enrollment ...
(Date:1/18/2017)... ... , ... Thirty-six startup companies in University City and Center City have been ... Economic Development in 2016 as part of the Keystone Innovation Zone (KIZ) Tax Credit ... and represent the highest number of awards to the largest number of companies in ...
(Date:1/18/2017)... Texas , Jan. 18, 2017  Caris ... and the Lustgarten Foundation, the largest private funder ... a clinical trial evaluating the impact of immunotherapy ... providing clinical trial enrollment services to identify potential ... facilitate communication between treating physicians and study investigators. ...
(Date:1/17/2017)... ... January 17, 2017 , ... LGC ... to its VALIDATE® SP2 calibration verification / linearity test kit. VALIDATE® SP2 evaluates ... Each VALIDATE® SP2 kit is prepared using the CLSI recommended “equal delta” method ...
Breaking Biology Technology: